What are the current guidelines for screening, diagnosis, and management of congenital TORCH infections in pregnant women and newborns?

Guidelines for Congenital TORCH Infections

Screening and Diagnosis

Routine universal prenatal TORCH screening is NOT recommended in the United States, in contrast to European practices. 1 Testing should be performed only when there are specific maternal symptoms (fever, thrombocytopenia, elevated liver enzymes) or fetal ultrasonographic abnormalities suggestive of congenital infection. 2

When to Test Pregnant Women

Maternal-related indications (higher yield):

• Fever with thrombocytopenia (7.1% positive rate)
• Elevated liver enzymes (3.0% positive rate)
• Gastroenteritis symptoms
• These indications detect approximately 10.8% of confirmed neonatal TORCH infections 2

Fetal-related indications (lower yield):

• Intrauterine growth restriction
• Ventriculomegaly/hydrocephalus
• Intracranial calcifications
• Polyhydramnios/oligohydramnios
• Only 0.8% positive rate for primary infection 2

Diagnostic Approach

Critical pitfall: Commercial laboratory TORCH panels are unreliable and should be avoided. 1 All positive or equivocal results from commercial labs must be confirmed at reference laboratories (PAMF-TSL: 650-853-4828 or NCCCT: 773-834-4152). 1

For Toxoplasmosis specifically:

• Negative IgG + negative IgM = not infected
• Positive IgG with low avidity = recent infection (likely during pregnancy)
• Positive IgG with high avidity = chronic infection (>12 months prior)
• Timing of maternal infection determines fetal risk and management 1

Treatment Protocols for Congenital Toxoplasmosis

Maternal Treatment During Pregnancy

For suspected/confirmed maternal infection BEFORE 18 weeks gestation:

• Spiramycin 1g (3 million IU) orally three times daily until delivery if fetus uninfected 1
• Spiramycin obtained through FDA (301-796-1600) at no cost 1
• Continue until amniocentesis can be performed (after 18 weeks)

For maternal infection AT OR AFTER 18 weeks, or confirmed fetal infection:

• Pyrimethamine + Sulfadiazine + Folinic acid 1
  • Pyrimethamine: 100mg/day divided twice daily × 2 days, then 50mg daily
  • Sulfadiazine: 75mg/kg loading dose, then 100mg/kg/day divided twice daily (max 4g/day)
  • Folinic acid: dose specified in guidelines to prevent bone marrow suppression
• Continue until delivery

German approach (achieves 4.8% transmission vs 30% in other European cohorts):

• Spiramycin until 16 weeks
• Switch to pyrimethamine/sulfadiazine after 16 weeks for minimum 4 weeks regardless of fetal status
• Continue combination therapy if fetal infection confirmed 1

Neonatal Treatment

For confirmed or suspected congenital toxoplasmosis, treat for 12 months: 1

• Pyrimethamine: 2mg/kg/day divided twice daily × 2 days, then 1mg/kg daily for 2-6 months (6 months if symptomatic), then 1mg/kg three times weekly
• Sulfadiazine: 100mg/kg/day divided twice daily
• Folinic acid: 10mg three times weekly 1

Add corticosteroids if:

• Severe chorioretinitis present
• CSF protein ≥1 g/dL
• Start only after 72 hours of anti-Toxoplasma therapy 1

Diagnostic Confirmation in Newborns

Gold standard: Persistence of positive Toxoplasma IgG beyond 12 months of age 1

Earlier diagnosis possible with:

• Positive IgM and/or IgA antibodies
• Positive PCR from amniotic fluid, blood, CSF, or urine
• Clinical manifestations + maternal acute infection + positive neonatal IgG 1

Complete neonatal evaluation includes:

• Detailed ophthalmologic exam by retinal specialist
• Head CT or ultrasound
• Abdominal ultrasound
• Brainstem auditory evoked responses
• Serial IgG titers every 4-6 weeks until disappearance (if uninfected) 1

Key Clinical Pitfalls

1. Never rely on commercial TORCH panels - false positives and negatives are common 1

2. Pyrimethamine access: No longer available in retail pharmacies. Must order through Walgreens specialty pharmacy (1-800-222-4991) with special enrollment form. Mark "STAT/URGENT" for same-day delivery. Available at no cost for uninsured patients. 1

3. Third trimester infections: Negative amniocentesis PCR does NOT rule out fetal infection when maternal infection occurs in third trimester (lower negative predictive value) 1

4. Treatment during pregnancy prevents transmission: The German data showing 1.3% first trimester transmission (vs expected 10-15%) supports aggressive early combination therapy 1

5. Disappearance of IgG during treatment does not rule out infection - must retest 1-3 months after treatment discontinuation 1

Other TORCH Pathogens

While the evidence provided focuses heavily on toxoplasmosis, the TORCH acronym traditionally includes:

• Toxoplasma (covered above)
• Others (syphilis, varicella, parvovirus B19, Zika, HIV, lymphocytic choriomeningitis virus)
• Rubella
• Cytomegalovirus (most common congenital infection)
• Herpes simplex virus

The traditional "TORCH test" panel is obsolete 3 - testing should be pathogen-specific based on clinical suspicion, not routine screening. 4, 5